论文部分内容阅读
目的观察肿瘤患者抗凝血酶Ⅲ(AT-Ⅲ)、蛋白C(PC)、蛋白S(PS)的活性变化并探讨其临床意义。方法用STA compact全自动凝血分析仪测定53例恶性肿瘤组和39例良性肿瘤组的AT-Ⅲ、PC、PS活性,并与51例正常对照组进行比较。结果恶性肿瘤组和良性肿瘤组的AT-Ⅲ、PC、PS活性明显低于正常对照组(P均<0.01),且恶性肿瘤组明显低于良性肿瘤组(P均<0.01),但在恶性肿瘤中消化系统与妇科抗凝物质活性差异无显著性(P>0.05)。结论抗凝物质AT-Ⅲ、PC、PS活性检测可以作为肿瘤患者诊断、疗效监测的重要指标。
Objective To observe the changes of antithrombin Ⅲ (AT-Ⅲ), protein C (PC) and protein S (PS) in patients with cancer and to explore its clinical significance. Methods The AT-Ⅲ, PC and PS activities of 53 malignant tumors and 39 benign tumors were detected by STA compact automated coagulation analyzer and compared with 51 normal controls. Results The AT-Ⅲ, PC, PS activities of malignant tumor group and benign tumor group were significantly lower than those of normal control group (all P <0.01), and were significantly lower in malignant group than in benign tumor group (all P <0.01) There was no significant difference in the activity of digestive system and gynecological anticoagulant in tumors (P> 0.05). Conclusion The detection of AT-Ⅲ, PC, PS activity of anticoagulant substances can be used as an important indicator in the diagnosis and curative effect monitoring of cancer patients.